Literature DB >> 22417271

Ovarian toxicity from sirolimus.

Matthias Braun, James Young, Cäcilia S Reiner, Diane Poster, Rudolf P Wüthrich, Andreas L Serra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22417271     DOI： 10.1056/NEJMc1113145

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

Review 1.  Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease.

Authors:  Max Christoph Liebau; Andreas Lucas Serra
Journal:  Pediatr Nephrol       Date:  2012-12-14       Impact factor: 3.714

Review 2.  New treatments for autosomal dominant polycystic kidney disease.

Authors:  Ming-Yang Chang; Albert C M Ong
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 3.  New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.

Authors:  Matthias Waldner; Daniel Fantus; Mario Solari; Angus W Thomson
Journal:  Br J Clin Pharmacol       Date:  2016-03-06       Impact factor: 4.335

Review 4.  Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

Authors:  Davide Bolignano; Suetonia C Palmer; Marinella Ruospo; Carmine Zoccali; Jonathan C Craig; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

Review 5.  Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD.

Authors:  Roberto Pagliarini; Christine Podrini
Journal:  Front Med (Lausanne)       Date:  2021-11-24

6.  Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial.

Authors:  Matthias Braun; James Young; Cäcilia S Reiner; Diane Poster; Fabienne Krauer; Andreas D Kistler; Paulus Kristanto; Xueqi Wang; Yang Liu; Johannes Loffing; Gustav Andreisek; Arnold von Eckardstein; Oliver Senn; Rudolf P Wüthrich; Andreas L Serra
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

7.  Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study.

Authors:  Quan Dong Nguyen; Mohamed A Ibrahim; Anthony Watters; Millena Bittencourt; Jithin Yohannan; Yasir J Sepah; James P Dunn; Joel Naor; Naveed Shams; Ovais Shaikh; Henry Alexander Leder; Diana V Do
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-02-11

8.  Pharmacological inhibition of mTORC1 prevents over-activation of the primordial follicle pool in response to elevated PI3K signaling.

Authors:  Deepak Adhikari; Sanjiv Risal; Kui Liu; Yan Shen
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

9.  Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy.

Authors:  Jianxin Ni; Fengqi Yan; Weijun Qin; Lei Yu; Geng Zhang; Fei Liu; Xiaojian Yang; Bo Yang; Chunlin Hao; Teng Wang; Pengfei Liu; Jianlin Yuan; Guojun Wu
Journal:  Sci Rep       Date:  2019-10-04       Impact factor: 4.379

10.  Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China.

Authors:  Cong Luo; Yu-Shi Zhang; Ming-Xin Zhang; Min-Feng Chen; Yuan Li; Lin Qi; Han-Zhong Li; Xiong-Bin Zu; Yi Cai
Journal:  Orphanet J Rare Dis       Date:  2021-07-03       Impact factor: 4.123
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.